Patty Dumond Sells 1,882 Shares of InVitae Corp (NVTA) Stock
InVitae Corp (NASDAQ:NVTA) VP Patty Dumond sold 1,882 shares of the business’s stock in a transaction dated Monday, October 9th. The stock was sold at an average price of $10.00, for a total transaction of $18,820.00. Following the sale, the vice president now directly owns 52,783 shares of the company’s stock, valued at approximately $527,830. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Patty Dumond also recently made the following trade(s):
- On Tuesday, October 10th, Patty Dumond sold 2,497 shares of InVitae Corp stock. The stock was sold at an average price of $10.00, for a total transaction of $24,970.00.
InVitae Corp (NASDAQ NVTA) traded up 0.10% during trading on Wednesday, reaching $9.95. 233,223 shares of the company were exchanged. The stock has a 50 day moving average price of $9.36 and a 200 day moving average price of $9.36. InVitae Corp has a 12 month low of $5.76 and a 12 month high of $11.88. The firm’s market capitalization is $433.26 million.
InVitae Corp (NASDAQ:NVTA) last posted its earnings results on Monday, August 7th. The medical research company reported ($0.66) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.02). InVitae Corp had a negative net margin of 199.20% and a negative return on equity of 153.27%. The business had revenue of $14.34 million for the quarter, compared to analysts’ expectations of $13.31 million. During the same quarter last year, the business posted ($0.77) earnings per share. The business’s revenue was up 157.0% compared to the same quarter last year. On average, analysts expect that InVitae Corp will post ($2.35) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/11/patty-dumond-sells-1882-shares-of-invitae-corp-nvta-stock.html.
A number of equities analysts recently weighed in on NVTA shares. BidaskClub upgraded shares of InVitae Corp from a “sell” rating to a “hold” rating in a research report on Tuesday, October 3rd. Zacks Investment Research upgraded shares of InVitae Corp from a “sell” rating to a “hold” rating in a research report on Friday, August 11th. Finally, J P Morgan Chase & Co restated an “overweight” rating and set a $15.00 price target (up from $14.00) on shares of InVitae Corp in a research report on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $13.50.
Several hedge funds and other institutional investors have recently modified their holdings of the company. California State Teachers Retirement System grew its holdings in shares of InVitae Corp by 24.1% during the second quarter. California State Teachers Retirement System now owns 69,009 shares of the medical research company’s stock worth $660,000 after buying an additional 13,400 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of InVitae Corp by 34.5% during the second quarter. The Manufacturers Life Insurance Company now owns 32,129 shares of the medical research company’s stock worth $307,000 after buying an additional 8,244 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of InVitae Corp during the second quarter worth about $202,000. State Street Corp grew its holdings in shares of InVitae Corp by 43.1% during the second quarter. State Street Corp now owns 577,978 shares of the medical research company’s stock worth $5,528,000 after buying an additional 174,016 shares in the last quarter. Finally, Royal Bank of Canada grew its holdings in shares of InVitae Corp by 131.3% during the second quarter. Royal Bank of Canada now owns 126,631 shares of the medical research company’s stock worth $1,210,000 after buying an additional 71,892 shares in the last quarter.
About InVitae Corp
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.
Receive News & Ratings for InVitae Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae Corp and related companies with MarketBeat.com's FREE daily email newsletter.